This literature review assesses the clinical potential of proton (1H) magnetic resonance spectroscopy (MRS) of breast lesions. We here illustrate the
basic principles of spectrum acquisition for volumes of interest, determined on the
basis of dynamic magnetic resonance imaging (MRI) and of MRS postprocessing. We discuss
the criteria for interpreting the spectrum with particular reference to the metabolic
significance of the peak of total choline containing compounds at 3.2 ppm, a marker
that is correlated with malignancy. We then summarise the findings obtained in lesion
characterisation (with a possible gain in specificity with respect to dynamic MRI),
the assessment of the effects of neoadjuvant chemotherapy, and the correlation reported
at high field between the tumour tissue concentration of choline-containing compounds
and the presence of lymph node metastases. Lastly, we outline the clinical use of
this technique as the final phase of a complete breast MR examination after intravenous
administration of paramagnetic contrast material for the dynamic study, with reference
to its use by radiologists dedicated to breast imaging.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2008 Published by Elsevier Inc.
